A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer

• Published in: International journal of oncology Vol. 46; no. 2; pp. 497 - 504
• Main Authors: OFUJI, KAZUYA, TADA, YOSHITAKA, YOSHIKAWA, TOSHIAKI, SHIMOMURA, MANAMI, YOSHIMURA, MAYUKO, SAITO, KEIGO, NAKAMOTO, YASUNARI, NAKATSURA, TETSUYA
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.02.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: acquired resistance; Antigens; Apoptosis - drug effects; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - therapy; Care and treatment; Cell Line, Tumor; Cell Proliferation - drug effects; CTL epitope; Cytomegalovirus; Cytotoxicity; Drug Resistance, Neoplasm - immunology; Drug therapy; EGFR T790M; Epidermal growth factor; Erlotinib Hydrochloride; Gene mutations; Genetic aspects; Health aspects; HLA-A2 Antigen - immunology; Humans; Immunotherapy; Kinases; Lung cancer; Lung cancer, Non-small cell; Medical prognosis; Mutation; non-small cell lung cancer; Peptides; Peptides - genetics; Peptides - immunology; Peptides - therapeutic use; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - immunology; Studies; Tumor necrosis factor-TNF; Japan; United States > US

Lung cancer is the leading cause of cancer-related deaths worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth f...